Transthyretin Amyloid Cardiomyopathy Clinical Trial

Safety And Efficacy Evaluation Of Fx-1006A In Subjects With Transthyretin Amyloidosis

Summary

This is a Phase 3, open-label study designed to obtain additional long-term safety and efficacy data for oral tafamidis (20 mg soft gelatin capsule) administered once daily (QD). In addition, this study continued to provide tafamidis to Val30Met subjects who had completed Protocol Fx-006 (a 1-year, open-label extension study to Protocol Fx-005 which was a randomized, double-blind, placebo-controlled, 18-month study to evaluate the safety and efficacy of tafamidis) or non-Val30Met subjects who had completed Protocol Fx1A-201 (a Phase 2, open-label study to evaluate TTR stabilization, safety, and tolerability of tafamidis) for up to 10 years or until subjects had access to tafamidis for ATTR-PN via prescription. Upon regulatory approval for the treatment of ATTR-PN in their respective country and access to prescription tafamidis, subjects may have been withdrawn from the study. Such subjects were considered study completers.

View Eligibility Criteria

Eligibility Criteria

Key Inclusion criteria:

Subject had successfully completed either Protocol Fx-006 or Fx-1A-201.
Male or female subjects with ATTR-PN who had not undergone liver or heart transplantation at time of enrollment.
If female, subject was post-menopausal, surgically sterilized, or willing to use an acceptable method of birth control

Key Exclusion criteria:

Chronic use of non-protocol approved non-steroidal anti-inflammatory drugs (NSAIDs)
Pregnant or breast feeding female subjects.
Clinically significant medical condition that, in the opinion of the investigator, would place the subject at an increased risk to participate in the study.
An alanine aminotransferase (ALT) and aspartate aminotransferase (AST) value >3 × upper limit of normal (ULN) that, in the medical judgment of the investigator, was due to reduced liver function or active liver disease.
Sexually active males with partners of childbearing potential not using highly effective contraception or not agreeing to continue highly effective contraception for at least 3 months after last dose of study drug.

Study is for people with:

Transthyretin Amyloid Cardiomyopathy

Phase:

Phase 3

Estimated Enrollment:

93

Study ID:

NCT00925002

Recruitment Status:

Completed

Sponsor:

Pfizer

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 9 Locations for this study

See Locations Near You

Johns Hopkins Hospital
Baltimore Maryland, 21287, United States
FLENI
Ciudad Autonoma de Buenos aires , C1428, Argentina
Hospital Universitário Clementino Fraga Filho -HUCFF Universidade Federal do Rio de Janeiro
Rio De Jameiro R.j., 21941, Brazil
Centre d'Investigation Clinique
Creteil , 94010, France
Universitatsklinikum Muenster
Muenster , 48149, Germany
Centro per lo Studio e la Cura delle Amiloidosi Sistemiche IRCCS - Policlinico San Matteo
Pavia , 27100, Italy
Centro Hospitalar Lisboa Norte, EPE- Hospital de Santa Maria
Lisboa , 1649-, Portugal
Unidade Clinica de Paramiloidose Centro Hospitalar do Porto, EPE - Hospital Geral de Santo António
Porto , 4099-, Portugal
FAP-Teamet Familjar Amyloidos
Umea , 90185, Sweden

How clear is this clinincal trial information?

Study is for people with:

Transthyretin Amyloid Cardiomyopathy

Phase:

Phase 3

Estimated Enrollment:

93

Study ID:

NCT00925002

Recruitment Status:

Completed

Sponsor:


Pfizer

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider